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Introduction

Infliximab (Remicade, Centocor, Inc., Malvern, PA), a chimeric
monoclonal antibody derived from both murine and human
antibody sequences and directed against TNF-α, is one of the
disease modifying anti-rheumatic drugs (DMARDs) used in
the treatment of psoriatic arthritis and other autoimmune
inflammatory conditions such as rheumatoid arthritis,
ankylosing spondylitis, and Crohn’s disease. It is commonly
used in combination with methotrexate for increased efficacy
and reduction of the development of anti-infliximab antibodies.
A concerning feature of infliximab therapy is its association with
an increased risk of infection or reactivation of diseases that can
cause pulmonary complications, most notably tuberculosis and
fungal infections. Additionally, there are a number of patients
who have developed non-infectious interstitial lung disease
following treatment with infliximab. These events usually occur
after the second to third infusions and can be preceded by a
course of methotrexate. In the setting of prior methotrexate
therapy, it is suggested that infliximab may potentiate the
manifestations of pulmonary toxicity due to methotrexate,
specifically methotrexate pneumonia.1 In the following case
report, we cite an example of the development of interstitial
lung disease after infliximab therapy in a patient with psoriatic
arthritis.

Case Presentation

A 59-year-old female with a previous medical history of asthma
and psoriatic arthritis with recent infliximab therapy presented
to the Emergency Department (ED) with a chief complaint of
progressive shortness of breath for two weeks. She experienced
chest tightness and dyspnea with exertion. She denied wheezing
and received minimal relief with nebulizers. She also stated
the presence of subjective fevers and sweating that started two
weeks ago. She denied leg swelling, weight gain, recent trips,
or sick contacts. Upon examination, she had difficulty speaking
due to shortness of breath and had rales on her left lung. No
wheezing or jugular venous distention was noted. She required
2 liters of oxygen by nasal cannula to maintain her saturations
at 96%. Cardiac examination was within normal limits. The rest
of the patient’s exam was normal. Initial chest x-ray was read as
prominence of interstitial lung markings.
Additional pertinent medical history includes: psoriatic
arthritis diagnosed 7 months prior to admission for which she
had received prior treatment. She had received intra-articular
steroid injections into the hand joints. After that therapy did
not relieve her symptoms she received two doses of weekly
methotrexate. This therapy was discontinued due to patient
intolerance. The patient began infliximab therapy three months
later. She had received three infusions of infliximab on a
biweekly schedule. The last infusion was administered two weeks
prior to admission. Her medications at presentation included:

metoprolol succinate (XL) 50 mg po qday, fenofibrate 145 mg
po qday, omega-3-fatty acid 4g po qday, irbesartan 150 mg po
qday, ezetemibe 10 mg po qday, rosuvastatin 20 mg po qday,
diphenhydramine 50 mg po qhs, furosemide 20 mg po qMWF,
fluticasone/salmeterol 250/50 mcg diskus day, alprazolam 1 mg
po qhs PRN, oxycodone/acetaminophen 5/325 mg po PRN, and
albuterol nebulizers PRN. The patient stated that she develops
seizures from gabapentin.
The patient’s medical and surgical histories also included: HTN,
hyperlipidemia, mitral valve prolapse, history of supraventricular tachycardia, anxiety, steroid-induced diabetes mellitus,
steroid-induced psychosis, thyroid cysts, MRSA pneumonia,
ocular surgery, ulnar nerve surgery, and breast lump removal.
Her social history is significant for drinking 2-3 alcoholic
beverages per week and no use of tobacco or recreational drugs.
She is normally fully functional and lives alone. She works for
a newspaper publisher.
Pertinent positives on review of systems included: chest
tightness, shortness of breath, cough, hoarseness, and epistaxis.
Pertinent negatives on review of systems included: no sputum
production, wheezing, edema.

Assessment

In the ED, the patient was treated with albuterol nebulizers.
After no improvement in her symptoms, the patient was
admitted to telemetry for further cardiac and respiratory
evaluation. Acute MI was ruled out with three negative
troponins and an unremarkable EKG. Echocardiogram showed
normal left ventricular size and function, an ejection fraction of
70 percent, and mild impaired relaxation of the left ventricle.
Her symptoms did not resolve with supplemental oxygen and
nebulizer treatment. Moxifloxacin was started for empiric
antibiotic coverage for community-acquired pneumonia. Room
air arterial blood gas was within normal limits. Despite this
laboratory value, the patient desaturated while ambulating on
room air to 77%. Chest CT (Figure 1) showed interstitial lung
disease with mild to moderate congestive heart failure. Despite
diuresis with furosemide, the patient’s symptoms did not resolve
so bronchoscopy was performed. Bronchoalveoloar lavage was
negative for malignant cells, PCP, fungus, and mycobacterium.
Transbronchial biopsy (Figure 2) was consistent with active
pneumonitis with interstitial inflammation, edema, and fibrosis.
Air spaces were lined by type II pneumocytes and contained
macrophages, fibrin and organizing pneumonia, which are
features consistent with drug-induced pneumonitis.

Management

The patient’s radiologic studies and pathology are consistent
with drug-induced pulmonary toxicity. After extensive review
of her medications, it was felt that the only drug that was
temporally related to the patient’s symptoms was
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infliximab. After nebulizers, antibiotics, and diuresis failed to
provide symptom relief, the patient was started on prednisone
50 mg orally daily. She was discharged 7 days after admission
on a prednisone taper and maintained on two liters portable
oxygen with mild improvement in her symptoms.

Discussion

Recent literature has implicated infliximab in the development
of interstitial pneumonitis.1 Many of the cases are in patients
with rheumatoid arthritis or Crohn’s Disease. 1,2 Often,
rheumatoid arthritis patients are concurrently receiving
methotrexate therapy to maximize disease modification.
Notably, the pulmonary toxicity can be quite severe. A prior
case series reports four patients with interstitial pneumonia and
one patient with bronchiolitis obliterans organizing pneumonia
following infliximab therapy. The patients had rheumatoid
arthritis and were not treated with methotrexate due to preexisting lung disease. Each of the patients except the patient
with bronchiolitis obliterans experienced rapidly declining
hospital courses and eventually expired from respiratory failure
despite steroids and ventilatory support.3

Figure 1. High Resolution Chest CT: Cross-section demonstrating
diffuse bilateral groundglass opacities and pulmonary edema.

The pathophysiology of infliximab induced pneumonitis is not
known. One possible theory is that infliximab may potentiate
the pulmonary toxicity of methotrexate. However, this does
not account for patients who were not receiving methotrexate
therapy. Animal models of bleomycin-induced lung toxicity have
shown that blocking TNF-α worsens toxicity. Other research
has shown that inhibition of TNF-α may increase proinflammatory cytokines. Additionally, when infliximab binds to TNFα on CD-4+ T cells and macrophages, proteolytic enzymes are
released which can lead to pulmonary damage.3
This is the first reported case of interstitial pneumonitis due to
infliximab in the psoriatic arthritis population. Our patient’s
exposure to methotrexate was limited to only a short treatment
of two doses, which was terminated secondary to intolerance.
Thus, the lack of a prior therapeutic methotrexate regimen and
the temporal relationship of the development of lung symptoms
with the start of infliximab infusion suggest that infliximab
alone may have induced interstitial lung disease.
As pulmonary complications associated with infliximab are
further documented, it becomes important to screen patients
for risk factors for pneumonitis prior to initiating therapy.
Some of the identified risk factors specifically for methotrexate
pneumonitis include preexisting lung disease, older age, diabetes,
hypoalbuminemia, and previous use of DMARDs.4
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Figure 2. H&E stain of tissue sample from transbronchial lung
biopsy. The above slide demonstrates active pneumonitis with
interstitial inflammation, edema, and fibrosis. Airspaces are
lined by type II pneumocytes and contain macrophages, fibrin
and organizing pneumonia.
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